The Food and Drug Administration yesterday released comparative performance data for 55 COVID-19 molecular diagnostic tests.

Test developers are required to assess their test’s performance against a reference panel of viral samples to receive emergency use authorization.

In the data, a lower product LoD (limit of detection) indicates a test’s ability to detect a smaller amount of viral material in a given sample, signaling a more sensitive test. FDA plans to update the data as it receives additional results to help inform laboratories, health care providers and patients about the relative performance of available tests.

In other news this week, FDA awarded a research contract to the University of Liverpool and global partners to sequence and analyze SARS-CoV-2 and other coronavirus samples to help inform the real-time performance of molecular-based diagnostics.

Related News Articles

Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…